HRP20241653T1 - Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju - Google Patents

Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju Download PDF

Info

Publication number
HRP20241653T1
HRP20241653T1 HRP20241653TT HRP20241653T HRP20241653T1 HR P20241653 T1 HRP20241653 T1 HR P20241653T1 HR P20241653T T HRP20241653T T HR P20241653TT HR P20241653 T HRP20241653 T HR P20241653T HR P20241653 T1 HRP20241653 T1 HR P20241653T1
Authority
HR
Croatia
Prior art keywords
sepiapterin
cocrystal
mir
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20241653TT
Other languages
English (en)
Croatian (hr)
Inventor
Eleonora MEZZAROMA
Christopher RABENDER
Ross MIKKELSEN
Vasily YAKOVLEV
Niel SMITH
Original Assignee
Ptc Therapeutics Mp, Inc.
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp, Inc., Virginia Commonwealth University filed Critical Ptc Therapeutics Mp, Inc.
Publication of HRP20241653T1 publication Critical patent/HRP20241653T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HRP20241653TT 2019-08-05 2020-08-05 Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju HRP20241653T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure
EP20758407.9A EP4009978B1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
HRP20241653T1 true HRP20241653T1 (hr) 2025-04-25

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241653TT HRP20241653T1 (hr) 2019-08-05 2020-08-05 Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN119837879A (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
KR20160068776A (ko) 2013-09-13 2016-06-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
AU2020324435B2 (en) 2026-03-19
IL290321B1 (en) 2026-04-01
PT4009978T (pt) 2024-11-05
RS66096B1 (sr) 2024-11-29
CA3146477A1 (en) 2021-02-11
EP4009978B1 (en) 2024-09-25
EP4454712A2 (en) 2024-10-30
EP4454712A3 (en) 2025-01-01
SMT202500089T1 (it) 2025-03-12
IL290321A (en) 2022-04-01
CN119837879A (zh) 2025-04-18
MX2022001535A (es) 2022-03-04
PL4009978T3 (pl) 2025-02-24
JP2022543655A (ja) 2022-10-13
FI4009978T3 (fi) 2024-11-01
ES2994060T3 (en) 2025-01-16
AU2020324435A1 (en) 2022-02-24
DK4009978T3 (da) 2024-10-14
US20220273661A1 (en) 2022-09-01
WO2021026247A1 (en) 2021-02-11
LT4009978T (lt) 2024-11-25
JP2025098011A (ja) 2025-07-01
BR112022002029A2 (pt) 2022-06-07
HUE069012T2 (hu) 2025-02-28
SI4009978T1 (sl) 2025-03-31
CN114555090A (zh) 2022-05-27
EP4009978A1 (en) 2022-06-15
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
HRP20241653T1 (hr) Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju
KR101584824B1 (ko) 건성 점막 치료용 오스모라이트-함유 제제
BR112018000592B1 (pt) Composição de desbloqueio de nariz congestionado tendo atividade antiviral
EP2249866A2 (de) Verwendung eines acetylsalicylsäuresalzes zur behandlung viraler infektionen
JP2021516219A (ja) ライノウイルス感染症の予防又は治療のための薬物
WO2016193894A1 (en) Treatment of respiratory disorders using ror- gamma inhibitors
ES2272689T3 (es) Dihidro-triterpenos en el tratamiento de infecciones virales, enfermedad cardiovascular, inflamacion, hipersensibilidad o dolor.
RU2011138178A (ru) рН-МОДУЛИРОВАННЫЕ СОСТАВЫ ДЛЯ ДОСТАВКИ В ЛЕГКИЕ
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
JP2008088189A5 (https=)
JPWO2021026247A5 (https=)
HRP20231209T1 (hr) Tekući pripravak za upotrebu u liječenju sluznice oro-faringo-laringo-ezofagealnog trakta
CN119074852B (zh) 用于清肺利咽的中药组合物、药物制剂及用途
US20130123364A1 (en) N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs
WO2021198220A1 (en) Treatment and prevention of secondary inflammation in patients suffering from a viral infection
WO2015131655A1 (zh) 佛司可林在防治慢性阻塞性肺病中的应用
CN105902534A (zh) 苯酚茶酸素在制备治疗或预防呼吸系统疾病药物中的应用
CN119770474B (zh) 9-羟基十五酸在制备防治肺损伤的药物中的应用
CN106727504B (zh) 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用
JP2002030000A (ja) 風邪根本治療法
CN119074852A (zh) 用于清肺利咽的中药组合物、药物制剂及用途
Arbak Effects of tear gases on the pulmonary system
CN104547044A (zh) 预防和治疗上呼吸道黏膜炎症的药用组合物、制备及应用
ES2987369T3 (es) Polímeros de acción doble en una película osmótica para administración tópica para tratar enfermedades inflamatorias y síndrome de liberación de citocinas
RU2749968C2 (ru) Способ борьбы с вирусными инфекциями